Shares in Novo Nordisk Plunge 14% as Next-Generation Obesity Drug Falls Short of Expectations

Novo Nordisk shares plunged 14% in pre-market trading after clinical trial data showed its new obesity drug CagriSema delivered less weight loss than Eli Lilly’s rival, prompting plans for further studies.